Skip to main content
logo
Bausch + Lomb Corporation (BLCO)
NYSE: BLCO · Real-Time Price · USD
15.46
+0.11 (0.72%)
At close: Jun 5, 2026, 4:00 PM EDT
15.48
+0.02 (0.13%)
After-hours: Jun 5, 2026, 7:00 PM EDT

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
U.S. and Puerto Rico Revenue
-2.55B2.41B
U.S. and Puerto Rico Revenue Growth
-5.51%24.77%
Total International Revenue
-2.56B2.38B
Total International Revenue Growth
-7.44%7.51%
Revenue (Total)
5.89B5.10B4.79B
Revenue (Total) Growth
15.44%6.47%15.56%

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Revenue
2.98B2.92B2.74B
Vision Care Revenue Growth
1.88%6.72%7.71%
Surgical Revenue
908.00M894.00M843.00M
Surgical Revenue Growth
1.57%6.05%9.91%
Ophthalmic Pharmaceuticals Revenue
1.32B1.28B1.21B
Ophthalmic Pharmaceuticals Revenue Growth
2.96%6.20%44.62%
Revenue (Other)
680.61M--
Revenue (Total)
5.89B5.10B4.79B
Revenue (Total) Growth
15.44%6.47%15.56%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Pharmaceuticals Revenue
1.13B1.08B969.00M
Pharmaceuticals Revenue Growth
4.07%11.56%56.80%
Devices Revenue
1.95B1.92B1.80B
Devices Revenue Growth
1.67%6.78%9.09%
OTC Revenue
1.87B1.83B1.72B
OTC Revenue Growth
1.96%6.38%7.01%
Branded and Other Generics Revenue
237.00M243.00M281.00M
Branded and Other Generics Revenue Growth
-2.47%-13.52%11.51%
Total Product Revenue
5.19B5.08B4.77B
Total Product Revenue Growth
2.09%6.41%15.57%
Other Product Revenue
22.00M21.00M17.00M
Other Product Revenue Growth
4.76%23.53%13.33%
Revenue (Total)
5.89B5.10B4.79B
Revenue (Total) Growth
15.44%6.47%15.56%

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Segment Profit
875.00M849.00M808.00M
Vision Care Segment Profit Growth
3.06%5.07%17.27%
Surgical Segment Profit
34.00M18.00M44.00M
Surgical Segment Profit Growth
88.89%-59.09%-12.00%
Ophthalmic Pharmaceuticals Segment Profit
313.00M258.00M256.00M
Ophthalmic Pharmaceuticals Segment Profit Growth
21.32%0.78%6.22%
Corporate Segment Profit
-666.00M-679.00M-614.00M
Amortization of Intangible Assets
-248.00M-258.00M-288.00M
Net Other Expense
-79.00M-75.00M-44.00M
Operating Income (Other)
-26.49M--
Operating Income (Total)
202.51M113.00M162.00M
Operating Income (Total) Growth
79.21%-30.25%24.62%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Revenue Change in Constant Currency
5.00%10.00%
Surgical Revenue Change in Constant Currency
6.00%11.00%
Ophthalmic Pharmaceuticals Revenue Change in Constant Currency
4.00%45.00%
Total Revenue Change in Constant Currency
6.00%17.00%
Updated Apr 29, 2026. Data Source: Fiscal.ai.